ESTRADIOL tablet

Land: Vereinigte Staaten

Sprache: Englisch

Quelle: NLM (National Library of Medicine)

Wirkstoff:

ESTRADIOL (UNII: 4TI98Z838E) (ESTRADIOL - UNII:4TI98Z838E)

Verfügbar ab:

Mylan Pharmaceuticals Inc.

INN (Internationale Bezeichnung):

ESTRADIOL

Zusammensetzung:

ESTRADIOL 0.5 mg

Verabreichungsweg:

ORAL

Verschreibungstyp:

PRESCRIPTION DRUG

Anwendungsgebiete:

Estradiol tablets are indicated in the: Estrogens should not be used in individuals with any of the following conditions:

Produktbesonderheiten:

Estradiol Tablets, USP are available containing 0.5 mg, 1 mg or 2 mg of estradiol, USP. The 0.5 mg tablets are white to off-white, round, scored tablets debossed with E to the left of the score and 3 to the right of the score on one side of the tablet and M on the other side. They are available as follows: NDC 0378-1452-01 bottles of 100 tablets NDC 0378-1452-05 bottles of 500 tablets The 1 mg tablets are pink, round, scored tablets debossed with E to the left of the score and 4 to the right of the score on one side of the tablet and M on the other side. They are available as follows: NDC 0378-1454-01 bottles of 100 tablets NDC 0378-1454-05 bottles of 500 tablets The 2 mg tablets are pale blue, round, scored tablets debossed with E to the left of the score and 5 to the right of the score on one side of the tablet and M on the other side. They are available as follows: NDC 0378-1458-77 bottles of 90 tablets NDC 0378-1458-01 bottles of 100 tablets NDC 0378-1458-05 bottles of 500 tablets Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. PHARMACIST: Dispense a Patient Information Leaflet with each prescription.

Berechtigungsstatus:

Abbreviated New Drug Application

Fachinformation

ESTRADIOL- ESTRADIOL TABLET
MYLAN PHARMACEUTICALS INC.
----------
ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER
Close clinical surveillance of all women taking estrogens is
important. Adequate diagnostic
measures, including endometrial sampling when indicated, should be
undertaken to rule out
malignancy in all cases of undiagnosed persistent or recurring
abnormal vaginal bleeding. There
is no evidence that the use of "natural" estrogens results in a
different endometrial risk profile
than "synthetic" estrogens at equivalent estrogen doses (see WARNINGS:
Malignant Neoplasms:
Endometrial Cancer).
CARDIOVASCULAR AND OTHER RISKS
Estrogens with or without progestins should not be used for the
prevention of cardiovascular
disease (see WARNINGS: Cardiovascular Disorders).
The Women’s Health Initiative (WHI) study reported increased risks
of myocardial infarction,
stroke, invasive breast cancer, pulmonary emboli and deep vein
thrombosis in postmenopausal
women (50 to 79 years of age) during 5 years of treatment with oral
conjugated estrogens (CE
0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg)
relative to placebo (see
CLINICAL PHARMACOLOGY: Clinical Studies).
The Women’s Health Initiative Memory Study (WHIMS), a substudy of
WHI, reported increased
risk of developing probable dementia in postmenopausal women 65 years
of age or older during 4
years of treatment with oral conjugated estrogens plus
medroxyprogesterone acetate relative to
placebo. It is unknown whether this finding applies to younger
postmenopausal women or to
women taking estrogen alone therapy (see CLINICAL PHARMACOLOGY:
Clinical Studies).
Other doses of oral conjugated estrogens with medroxyprogesterone
acetate, and other
combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical
trials and, in the absence of comparable data, these risks should be
assumed to be similar. Because
of these risks, estrogens with or without progestins should be
prescribed at the lowest effective
doses and for the short